| Name | Title | Contact Details |
|---|
Atlanta Design Group (ADG) is a Full-Service Interior Design Company made up of a group of specialized brands offering numerous products and services supporting the interior design and design-build trades. ADG was organized to meet the needs of the design profession in an ever-changing global market. By diversifying our products and services and providing our clients with a customer experience designed to span the lifetime of the project, ADG is redefining how the design industry conducts business. Atlanta Design Group covers all the bases to include interior design; specialized marketing; furniture and accessories; outdoor living; kitchen & bath; specialty construction products, fine art and framing, lighting solutions and installation and logistics services making your job more streamlined than ever. We are confident that forming a business relationship with our company is the absolute best move you can make towards growing and advancing your business to the next level. Working together, Atlanta Design Group is a single, turnkey source working for you. One Company, One Source, One Solution The Power of One
Bimeda is an Ireland-based company that develops, manufactures and markets veterinary and animal care products.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.